Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT03229096
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib plus XELOX — DRUG
    three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle. Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week). Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks.

Study Details

Apatinib plus XELOX regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer PatientsWith lymph node metastasis

Key Dates

Start date
Feb 1, 2017
Status verified
Jun 2019
Primary completion
Nov 1, 2021
Completion
Dec 1, 2021

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus XELOX
    Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 3 months ]

Central Contacts

Related Studies